Target intelligence / Profile preview

RNA-binding protein MEX3A (MEX3A)

Target
MEX3A
Molecular classification
RNA-binding protein (contains two KH [K homology] RNA-binding domains), E3 ubiquitin ligase (contains a C-terminal RING finger domain)
01

Overview

RNA-binding protein MEX3A is a member of the MEX-3 family of evolutionarily conserved RNA-binding proteins defined by two KH (K homology) domains and a carboxy-terminal RING finger domain. MEX3A acts as a post-transcriptional regulator, binding to 3' untranslated regions of target mRNAs, promoting mRNA decay, and influencing translation efficiency. It can shuttle between the nucleus and cytoplasm, localizing in P-bodies—sites of mRNA turnover. In mammals, MEX3A is implicated in critical cellular processes such as stem cell self-renewal, the maintenance of undifferentiated cell states, and the regulation of proliferation and cell cycle progression. Overexpression of MEX3A has been consistently linked to heightened tumorigenicity and poor prognosis in several cancers, making it of interest as a therapeutic target and biomarker for patient selection[1][2][5][8].

Other names
MEX3AMEX-3ARKHD4RNF162Ring finger and KH domain-containing protein 4Ring finger and KH domain containing 4
02

Mechanism of action

Inhibitors targeting MEX3A would likely act by blocking its RNA binding activity or disrupting its E3 ubiquitin ligase function, thereby stabilizing target tumor-suppressive mRNAs and attenuating proliferative signaling

03

Biological functions

Post-transcriptional regulation (mediates mRNA decay by binding to 3' UTR regions)Cell cycle regulation (controls G1/S transition and proliferation)Maintenance of stem cell self-renewal and cell differentiationRegulation of mRNA stability and translation (shuttles between nucleus and cytoplasm, involved in P-bodies)
04

Disease associations

Cancer (upregulated in several cancers and promotes abnormal cell proliferation)
05

Safety considerations

Risks from targeting cell cycle and stemness regulators, including potential impacts on normal stem cell renewal and tissue homeostasis.Lack of target selectivity due to functional overlap in RNA processing and ubiquitin ligase activity among different MEX3 family members and related proteins.
06

Interacting drugs

None currently approved or widely reported in public domain; targeted drug development is still in research stages.
07

Biomarkers

MEX3A expression levels (potentially for cancer patient stratification and prognosis)

Beyond the preview

Go deeper on RNA-binding protein MEX3A (MEX3A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA-binding protein MEX3A (MEX3A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call